← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

ENDRA Life Sciences Inc. (NDRA) 10-Year Financial Performance & Capital Metrics

NDRA • • Industrial / General
HealthcareDiagnostics & ResearchDigital Health & Point-of-Care DiagnosticsRapid Diagnostic Technologies
AboutENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Show more
  • Revenue $0
  • EBITDA -$11M -5.1%
  • Net Income -$12M -14.4%
  • EPS (Diluted) -10.25 -74.0%
  • Gross Margin -
  • EBITDA Margin -
  • Operating Margin -
  • Net Margin -
  • ROE -280.02% -79.0%
  • ROIC -517.6% -99.5%
  • Debt/Equity 0.23 +227.5%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Share count reduced 34.3% through buybacks

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Weak momentum: RS Rating 16 (bottom 16%)
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-
TTM-

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM8.36%

EPS CAGR

10Y-
5Y-
3Y-
TTM-138.86%

ROCE

10Y Avg-363.04%
5Y Avg-163.6%
3Y Avg-173.02%
Latest-223.08%

Peer Comparison

Rapid Diagnostic Technologies
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
CHEKCheck-Cap Ltd.10.24M1.75-0.41-226.19%
NDRAENDRA Life Sciences Inc.5.21M4.47-0.44-5.95%0.23
INBSIntelligent Bio Solutions Inc.17.54M14.42-7.21-1.9%-330.06%-317.07%0.10

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+1.41M515.58K351.62K6.17K000000
Revenue Growth %1.52%-0.63%-0.32%-0.98%-1%-----
Cost of Goods Sold+666.23K235.88K172.78K0115.01K165.25K224.41K234.26K275.45K0
COGS % of Revenue0.47%0.46%0.49%-------
Gross Profit+743.83K279.7K178.84K6.17K-115.01K-165.25K-224.41K-234.26K-275.45K0
Gross Margin %0.53%0.54%0.51%1%------
Gross Profit Growth %1.48%-0.62%-0.36%-0.97%-19.63%-0.44%-0.36%-0.04%-0.18%1%
Operating Expenses+2.31M2.07M4.8M8.74M10.73M11.34M11.27M12.92M10.25M10.82M
OpEx % of Revenue1.64%4.02%13.66%1415.23%------
Selling, General & Admin1.27M1.58M2.87M4.02M4.15M5.42M5.79M6.37M5.24M7.63M
SG&A % of Revenue0.9%3.06%8.17%650.34%------
Research & Development1.04M495.38K1.93M4.72M6.57M5.92M5.48M6.55M5M3.19M
R&D % of Revenue0.74%0.96%5.49%764.9%------
Other Operating Expenses0-5.82K00000000
Operating Income+-1.57M-1.79M-4.63M-9.02M-10.84M-11.5M-11.5M-13.16M-10.52M-10.82M
Operating Margin %-1.11%-3.48%-13.16%-1460.8%------
Operating Income Growth %-0.03%-0.14%-1.58%-0.95%-0.2%-0.06%0%-0.14%0.2%-0.03%
EBITDA+-1.5M-1.73M-4.56M-8.95M-10.73M-11.34M-11.27M-12.92M-10.25M-10.77M
EBITDA Margin %-1.06%-3.35%-12.98%-1449.74%------
EBITDA Growth %-0%-0.15%-1.64%-0.96%-0.2%-0.06%0.01%-0.15%0.21%-0.05%
D&A (Non-Cash Add-back)72.22K64.94K61.48K68.32K115.01K165.25K224.41K234.26K275.45K46.49K
EBIT-1.57M-1.79M-4.63M-9.07M-10.95M-11.49M-11.23M-13.18M-10.06M-10.82M
Net Interest Income+000-729.24K-2.35M-232.19K0-21.53K00
Interest Income00002.35K2320000
Interest Expense000729.24K2.36M232.43K021.53K00
Other Income/Expense-710.63K-983.61K-750.9K-777.25K-2.46M-223.58K267.06K-21.53K460.49K-690.8K
Pretax Income+-2.28M-2.78M-5.38M-9.8M-13.31M-11.73M-11.23M-13.18M-10.06M-11.51M
Pretax Margin %-1.62%-5.38%-15.29%-1586.7%------
Income Tax+0983.61K00000000
Effective Tax Rate %1%1%1%1%1%1%1%1%1%1%
Net Income+-2.28M-2.78M-5.38M-9.8M-13.31M-11.73M-11.23M-13.18M-10.06M-11.51M
Net Margin %-1.62%-5.38%-15.29%-1586.7%------
Net Income Growth %-0.05%-0.22%-0.94%-0.82%-0.36%0.12%0.04%-0.17%0.24%-0.14%
Net Income (Continuing)-2.28M-2.78M-5.38M-9.8M-13.31M-11.73M-11.23M-13.18M-10.06M-11.51M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-11.67-14.21-27.47-43.49-41.48-12.47-5.47-6.84-5.89-10.25
EPS Growth %0.84%-0.22%-0.93%-0.58%0.05%0.7%0.56%-0.25%0.14%-0.74%
EPS (Basic)-11.67-14.21-27.47-43.49-41.48-12.47-5.47-4.57-5.89-10.25
Diluted Shares Outstanding195.35K195.35K195.75K225.24K375K959.61K2.05M1.93M1.71M1.12M
Basic Shares Outstanding195.35K195.35K195.75K225.24K375K959.61K2.05M1.93M1.71M1.12M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+126.62K195.59K5.88M6.95M6.54M8.21M12.09M8.53M3.03M3.43M
Cash & Short-Term Investments19.13K144.95K5.6M6.47M6.17M7.23M9.46M4.89M2.83M3.23M
Cash Only19.13K144.95K5.6M6.47M6.17M7.23M9.46M4.89M2.83M3.23M
Short-Term Investments0000000000
Accounts Receivable006.85K0000000
Days Sales Outstanding--7.11-------
Inventory99K40.1K191.68K59.44K113.44K589.62K1.28M2.64M00
Days Inventory Outstanding54.2462.06404.92-360.021.3K2.09K4.12K--
Other Current Assets8.49K10.54K14.25K273.31K130.7K00000
Total Non-Current Assets+360.1K295.17K241.55K273.23K641.17K557.24K780.53K747.46K3.72M1.02M
Property, Plant & Equipment360.1K295.17K241.55K273.23K641.17K551.25K774.54K741.47K465.87K647.29K
Fixed Asset Turnover3.92x1.75x1.46x0.02x------
Goodwill0000000000
Intangible Assets0000000000
Long-Term Investments0000000000
Other Non-Current Assets000005.99K5.99K5.99K3.26M371.4K
Total Assets+486.72K490.76K6.12M7.22M7.18M8.76M12.87M9.27M6.75M4.45M
Asset Turnover2.90x1.05x0.06x0.00x------
Asset Growth %-0.31%0.01%11.48%0.18%-0.01%0.22%0.47%-0.28%-0.27%-0.34%
Total Current Liabilities+236.42K1.38M848.21K974.58K2.07M986.66K1.54M1.7M903.1K605.23K
Accounts Payable80.94K227.74K780.26K631.47K1.28M402.91K791.05K613.96K360.4K269.68K
Days Payables Outstanding44.35352.411.65K-4.06K889.941.29K956.62477.57-
Short-Term Debt0949.98K00364.26K83.87K117.13K28.48K28.48K0
Deferred Revenue (Current)0206.81K0-23000000
Other Current Liabilities072K022.51K235.35K00158.93K148.79K169.72K
Current Ratio0.54x0.14x6.93x7.13x3.15x8.32x7.83x5.00x3.36x5.67x
Quick Ratio0.12x0.11x6.71x7.07x3.10x7.72x7.00x3.45x3.36x5.67x
Cash Conversion Cycle---1.24K-------
Total Non-Current Liabilities+0000342.81K608.99K546.63K365.92K192.06K1.29M
Long-Term Debt00000337.08K28.48K000
Capital Lease Obligations0000342.81K271.91K518.15K365.92K192.06K487.48K
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities000000000799.28K
Total Liabilities236.42K1.38M848.21K974.58K2.42M1.6M2.09M2.07M1.1M1.89M
Total Debt+0949.98K023773.27K769.34K796.09K546.63K394.4K584.42K
Net Debt-19.13K805.02K-5.6M-6.47M-5.4M-6.46M-8.67M-4.34M-2.44M-2.65M
Debt / Equity---0.00x0.16x0.11x0.07x0.08x0.07x0.23x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage----12.37x-4.60x-49.49x--611.04x--
Total Equity+250.3K-893.77K5.28M6.25M4.76M7.17M10.78M7.2M5.66M2.56M
Equity Growth %-0.59%-4.57%6.9%0.18%-0.24%0.51%0.5%-0.33%-0.21%-0.55%
Book Value per Share1.28-4.5826.9527.7412.707.475.273.733.312.28
Total Shareholders' Equity250.3K-893.77K5.28M6.25M4.76M7.17M10.78M7.2M5.66M2.56M
Common Stock2532533927428423.4K2123171.04K53
Retained Earnings-9.74M-12.52M-17.9M-27.69M-45.22M-57.34M-68.69M-81.87M-91.93M-103.44M
Treasury Stock0000000000
Accumulated OCI-208.09K-276.15K-337.63K-405.95K43.53K10.79K13.86K6.07K5.23K0
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-842.73K-1.32M-3.3M-7.7M-8.59M-10.77M-11.12M-12.77M-9.55M-7.4M
Operating CF Margin %-0.6%-2.55%-9.39%-1247.57%------
Operating CF Growth %0.4%-0.56%-1.51%-1.33%-0.12%-0.25%-0.03%-0.15%0.25%0.22%
Net Income-2.28M-2.78M-5.38M-9.8M-13.31M-11.73M-11.23M-13.18M-10.06M-11.51M
Depreciation & Amortization72.22K64.94K61.48K68.32K115.01K165.25K224.41K234.26K275.45K206.17K
Stock-Based Compensation309.84K230.33K1K1.37K1.4K2.1M1.44M1.2M996.43K571.92K
Deferred Taxes25K000-1.4K-2.1M0000
Other Non-Cash Items686.34K909.5K1.72M2.38M4M2.33M-298.73K1.39K162.91K3.2M
Working Capital Changes343.07K254.98K298.66K-359.08K597.83K-1.55M-1.26M-1.03M-923.32K134.08K
Change in Receivables00-6.85K6.85K-760.14K834.99K-491.1K000
Change in Inventory139.98K58.9K-151.57K-155.31K-54K-476.18K-694.96K-1.36M138.04K235.73K
Change in Payables202.59K198.13K528.29K-6.19M760.14K-834.99K491.1K111.58K-822.26K-198.87K
Cash from Investing+-133.81K0-7.86K-100K-43.59K-51.33K-45K-202.58K-24.72K-12.8K
Capital Expenditures-133.81K0-7.86K-100K-43.59K-51.33K-45K-202.58K-33.88K-16K
CapEx % of Revenue0.09%-0.02%16.2%------
Acquisitions----------
Investments----------
Other Investing000000009.16K3.2K
Cash from Financing+839.22K1.44M8.77M8.67M8.34M11.88M13.4M8.4M7.52M7.81M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000-4.22M-395.55K-121.07K-7.79K-840-5.23K
Share Repurchases----------
Other Financing05K8.59M7.74M10.06M5.15M2.91M01.04M1
Net Change in Cash----------
Free Cash Flow+-976.54K-1.32M-3.31M-7.8M-8.63M-10.82M-11.17M-12.97M-9.58M-7.42M
FCF Margin %-0.69%-2.55%-9.41%-1263.76%------
FCF Growth %0.42%-0.35%-1.51%-1.36%-0.11%-0.25%-0.03%-0.16%0.26%0.23%
FCF per Share-5.00-6.73-16.90-34.64-23.02-11.28-5.46-6.72-5.61-6.61
FCF Conversion (FCF/Net Income)0.37x0.47x0.61x0.79x0.65x0.92x0.99x0.97x0.95x0.64x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-532.75%--245.43%-170.02%-241.73%-196.57%-125.11%-146.53%-156.42%-280.02%
Return on Invested Capital (ROIC)-345.98%-1887.02%----24273.5%-609.42%-396.24%-259.49%-517.6%
Gross Margin52.75%54.25%50.86%100%------
Net Margin-161.64%-538.3%-1529.19%-158669.6%------
Debt / Equity---0.00x0.16x0.11x0.07x0.08x0.07x0.23x
Interest Coverage----12.37x-4.60x-49.49x--611.04x--
FCF Conversion0.37x0.47x0.61x0.79x0.65x0.92x0.99x0.97x0.95x0.64x
Revenue Growth152.09%-63.44%-31.8%-98.24%-100%-----

Frequently Asked Questions

Growth & Financials

ENDRA Life Sciences Inc. (NDRA) grew revenue by 0.0% over the past year. Growth has been modest.

ENDRA Life Sciences Inc. (NDRA) reported a net loss of $8.8M for fiscal year 2024.

Dividend & Returns

Yes, ENDRA Life Sciences Inc. (NDRA) pays a dividend with a yield of 0.10%. This makes it attractive for income-focused investors.

ENDRA Life Sciences Inc. (NDRA) has a return on equity (ROE) of -280.0%. Negative ROE indicates the company is unprofitable.

ENDRA Life Sciences Inc. (NDRA) had negative free cash flow of $5.6M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.